Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

New Method Identifies Anthrax Bacteria Faster Than Current Approaches

By Labmedica International staff writers
Posted on 06 Mar 2014
Caption: The anthrax bacteria – Bacillus anthracis, transmitted mainly through inhalation or skin abrasions (Photo courtesy of University of Missouri).
Caption: The anthrax bacteria – Bacillus anthracis, transmitted mainly through inhalation or skin abrasions (Photo courtesy of University of Missouri).
A new method has been developed for rapid diagnostic detection and antibiotic susceptibility determination of the pathogenic Bacillus anthracis using a bioluminescent reporter phage.

Although anthrax is a treatable disease, positive patient prognosis is dependent on rapid diagnosis and therapy. A team at the University of Missouri (MU; Columbia, MO, USA) assessed a bioluminescent reporter phage, developed by David Schofield at Guild BioSciences (Charleston, SC, USA), for its value as a clinical diagnostic tool for Bacillus anthracis. The reporter phage based method, published in the Journal of Microbiological Methods (November 2013), detects live B. anthracis strains by transducing a bioluminescent phenotype. It was found to rule out false positives – displaying species specificity by its inability, or significantly reduced ability, to detect members of the closely related Bacillus cereus group and other common bacterial pathogens.

The method detects low levels of B. anthracis, at clinically relevant bacterial concentrations, within 5 hours. “Normally to identify whether an organism is present, you have to extract the material, culture it, and then pick colonies to examine that might turn out to be anthrax bacteria,” said Prof. George Stewart, PhD, medical bacteriologist. “Then you conduct chemical testing which takes some time—a minimum of 24 to 48 hours. Using this newly-identified method, we can reduce that time to about 5 hours.” The method also provides antibiotic susceptibility information that mirrors the CLSI method, except that data are obtained at least 5-fold faster.

In addition to saving lives, the new method could also save on high clean up and decontamination costs of bioterrorism attacks. These costs for the post-9/11 2001 anthrax letters attack totaled USD 3.2 million, according to a 2012 report. “In the years since the post-9/11 postal attacks, we haven’t had any bona fide anthrax attacks,” said Prof. Stewart; “That doesn’t mean that it’s not going to happen, we just have to be prepared.” Current methods take 1–3 days to produce definitive results for anthrax. The new detection method would potentially alert of a negative result 5 hours into clean-up efforts instead of 1–3 days into expensive decontamination.

Related Links:
University of Missouri at Columbia
Guild Biosciences


Dubai Bio Expo-2015
KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.